Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
LEU-001 by Leucid Bio for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
LEU-001 is under clinical development by Leucid Bio and currently in Phase I for Recurrent Head And Neck Squamous Cell...